These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 23632723)

  • 1. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.
    Dobson SR; McNeil S; Dionne M; Dawar M; Ogilvie G; Krajden M; Sauvageau C; Scheifele DW; Kollmann TR; Halperin SA; Langley JM; Bettinger JA; Singer J; Money D; Miller D; Naus M; Marra F; Young E
    JAMA; 2013 May; 309(17):1793-802. PubMed ID: 23632723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial.
    Neuzil KM; Canh DG; Thiem VD; Janmohamed A; Huong VM; Tang Y; Diep NT; Tsu V; LaMontagne DS
    JAMA; 2011 Apr; 305(14):1424-31. PubMed ID: 21486975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women.
    Iversen OE; Miranda MJ; Ulied A; Soerdal T; Lazarus E; Chokephaibulkit K; Block SL; Skrivanek A; Nur Azurah AG; Fong SM; Dvorak V; Kim KH; Cestero RM; Berkovitch M; Ceyhan M; Ellison MC; Ritter MA; Yuan SS; DiNubile MJ; Saah AJ; Luxembourg A
    JAMA; 2016 Dec; 316(22):2411-2421. PubMed ID: 27893068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.
    Puthanakit T; Huang LM; Chiu CH; Tang RB; Schwarz TF; Esposito S; Frenette L; Giaquinto C; McNeil S; Rheault P; Durando P; Horn M; Klar M; Poncelet S; De Simoni S; Friel D; De Muynck B; Suryakiran PV; Hezareh M; Descamps D; Thomas F; Struyf F
    J Infect Dis; 2016 Aug; 214(4):525-36. PubMed ID: 26908726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
    Bergman H; Buckley BS; Villanueva G; Petkovic J; Garritty C; Lutje V; Riveros-Balta AX; Low N; Henschke N
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31755549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women.
    Hu YM; Guo M; Li CG; Chu K; He WG; Zhang J; Gu JX; Li J; Zhao H; Wu XH; Lin B; Lin ZJ; Yao XM; Li YF; Wei F; Huang Y; Su YY; Zhu FC; Huang SJ; Pan HR; Wu T; Zhang J; Xia NS
    Sci China Life Sci; 2020 Apr; 63(4):582-591. PubMed ID: 31231780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of 2-Dose HPV Vaccine Series for Postpartum Women: An Open-Label, Nonrandomized, Noninferiority Trial.
    Moss CF; Wang R; Sao S; Chou B; Perin J; Lander ME; Thaker SM; Mann M; Coleman JS
    JAMA Netw Open; 2024 Jan; 7(1):e2352996. PubMed ID: 38285445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study.
    Romanowski B; Schwarz TF; Ferguson LM; Peters K; Dionne M; Schulze K; Ramjattan B; Hillemanns P; Catteau G; Dobbelaere K; Schuind A; Descamps D
    Hum Vaccin; 2011 Dec; 7(12):1374-86. PubMed ID: 22048171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial.
    Sharma H; Parekh S; Pujari P; Shewale S; Desai S; Bhatla N; Joshi S; Pimple S; Kawade A; Balasubramani L; Thomas A; Suri V; Lalwani S; Uday R; Kamath V; Mandal R; Rajeswar A; Peedicayil A; Poli UR; Banerjee D; Sankaranarayanan R; Basu P; Muwonge R; Gairola S; Dogar V; Rao H; Shaligram U
    Lancet Oncol; 2023 Dec; 24(12):1321-1333. PubMed ID: 37949086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years.
    Schwarz TF; Huang LM; Valencia A; Panzer F; Chiu CH; Decreux A; Poncelet S; Karkada N; Folschweiller N; Lin L; Dubin G; Struyf F
    Hum Vaccin Immunother; 2019; 15(7-8):1970-1979. PubMed ID: 31268383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7.
    Konno R; Dobbelaere KO; Godeaux OO; Tamura S; Yoshikawa H
    Int J Gynecol Cancer; 2009 Jul; 19(5):905-11. PubMed ID: 19574783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.
    Romanowski B; Schwarz TF; Ferguson L; Peters K; Dionne M; Behre U; Schulze K; Hillemanns P; Suryakiran P; Thomas F; Struyf F
    Hum Vaccin Immunother; 2016; 12(1):20-9. PubMed ID: 26176261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study.
    Sankaranarayanan R; Joshi S; Muwonge R; Esmy PO; Basu P; Prabhu P; Bhatla N; Nene BM; Shaw J; Poli URR; Verma Y; Zomawia E; Pimple S; Tommasino M; Pawlita M; Gheit T; Waterboer T; Sehr P; Pillai MR;
    Vaccine; 2018 Aug; 36(32 Pt A):4783-4791. PubMed ID: 29551226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis.
    Donken R; Knol MJ; Bogaards JA; van der Klis FR; Meijer CJ; de Melker HE
    J Infect; 2015 Jul; 71(1):61-73. PubMed ID: 25709084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HML; Lee BW; Rombo L; Tan NC; Rouzier R; De Simoni S; Suryakiran P; Hezareh M; Thomas F; Folschweiller N; Struyf F
    Vaccine; 2018 Jan; 36(1):98-106. PubMed ID: 29174109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls.
    Pedersen C; Breindahl M; Aggarwal N; Berglund J; Oroszlán G; Silfverdal SA; Szüts P; O'Mahony M; David MP; Dobbelaere K; Dubin G; Descamps D
    J Adolesc Health; 2012 Jan; 50(1):38-46. PubMed ID: 22188832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence of Immunity When Using Different Human Papillomavirus Vaccination Schedules and Booster-Dose Effects 5 Years After Primary Vaccination.
    Lazcano-Ponce E; Torres-Ibarra L; Cruz-Valdez A; Salmerón J; Barrientos-Gutiérrez T; Prado-Galbarro J; Stanley M; Muñoz N; Herrero R; Hernández-Ávila M
    J Infect Dis; 2019 Jan; 219(1):41-49. PubMed ID: 30085139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
    Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
    Apter D; Wheeler CM; Paavonen J; Castellsagué X; Garland SM; Skinner SR; Naud P; Salmerón J; Chow SN; Kitchener HC; Teixeira JC; Jaisamrarn U; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Mindel A; de Sutter P; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
    Clin Vaccine Immunol; 2015 Apr; 22(4):361-73. PubMed ID: 25651922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of 2 and 3 Doses of the Quadrivalent Human Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized Clinical Trial.
    Donken R; Dobson SRM; Marty KD; Cook D; Sauvageau C; Gilca V; Dionne M; McNeil S; Krajden M; Money D; Kellner J; Scheifele DW; Kollmann T; Bettinger JA; Liu S; Singer J; Naus M; Sadarangani M; Ogilvie GS
    Clin Infect Dis; 2020 Aug; 71(4):1022-1029. PubMed ID: 31617568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.